Form 4 for DGX Quest Diagnostics
Accepted 2026-06-08 16:32:30 ET · period of report 2026-06-04 · accession 0001022079-26-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-08 16:32 | 2026-06-04 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M - OptEx | $124.22 | +8,147 | 21.7K | +60% | +$1.01M |
| DT | 2026-06-08 16:32 | 2026-06-04 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale+OE | $200.00 | -8,147 | 13.5K | -38% | -$1.63M |
| DMT | 2026-06-08 16:32 | 2026-06-04 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M - OptEx | $124.22 | -8,147 | 0 | -100% | -$1.01M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-04 | M | A | 3,320 | $127.72 | 16,830 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-06-04 | M | A | 4,827 | $121.81 | 21,657 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. |
| 3 | Common | Common Stock | 2026-06-04 | S | D | 8,147 | $200.00 | 13,510 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F2) The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. |
| 4 | Derivative | Non-Qualifed Stock Option (right to buy) | 2026-06-04 | M | D | 3,320 | $127.72 | 0 | D | $127.72 · — to 2032-02-24 | 3,320 Common Stock | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F4) The options vested in three annual installments beginning with the first on February 24, 2023, the second on February 24, 2024 and the final on February 24, 2025. |
| 5 | Derivative | Non-Qualifed Stock Option (right to buy) | 2026-06-04 | M | D | 4,827 | $121.81 | 0 | D | $121.81 · — to 2031-02-17 | 4,827 Common Stock | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F5) The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. |